Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. 14, 859-868
- https://doi.org/10.2147/PPA.S246757
Abstract
Objective: The severity of breakthrough cancer pain (BTcP) impacts patients' quality of life, increases the risk of anxiety and depression, lowers functional capacities, and may lead to poor compliance with cancer treatments. The aim of the current study was to assess, in a real-life setting, patient satisfaction with a fentanyl-pectin-nasal-spray (FPNS) for BTcP management in head and neck (H&N) cancer patients treated by radiotherapy. Materials and Methods: This non-interventional, prospective study was conducted in 92 adult H&N-cancer patients undergoing radiotherapy and who started FPNS treatment for BTcP. Throughout the radiotherapy period, the patients completed self-diaries to assess their BTcP episodes, FPNS use, satisfaction on FPNS efficiency (primary outcome), tolerability and ease of use. Results: Prior to FPNS treatment, 86% of the patients were experiencing <= 4 BTcP episodes/day. During the radiotherapy period, the BTcP episodes were treated with a median dose of 100 mu g of FPNS. Patients were "satisfied/very-satisfied" with the efficiency (73% of assessments), ease of use (87% of assessments) and tolerability (87% of assessments) of FPNS. In total, 27% of patients reported at least one adverse event related to FPNS and 4% of patients discontinued treatment due to adverse events. None of the adverse events were serious. Patient quality of life was maintained throughout the radiotherapy period. Conclusion: This study showed, in a real-life setting, that a clear majority of H&N cancer patients treated with FPNS for BTcP throughout radiotherapy expressed satisfaction with this analgesic treatment.This publication has 22 references indexed in Scilit:
- Development ofin vitromodels to demonstrate the ability of PecSys®, anin situnasal gelling technology, to reduce nasal run-off and dripDrug Development and Industrial Pharmacy, 2012
- Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate in Breakthrough Cancer PainJournal of Pain and Symptom Management, 2011
- A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer painPain, 2010
- Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, Part 1: Prevalence and characteristicsJournal of Opioid Management, 2010
- Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudesAnnals of Oncology, 2009
- Prevalence of pain in patients with cancer: a systematic review of the past 40 yearsAnnals of Oncology, 2007
- Chronic Pain in the Cancer Survivor: A New FrontierPain Medicine, 2007
- Episodic (breakthrough) painCancer, 2002
- Pharmacology of opioid analgesia: clinical principlesPublished by Cambridge University Press (CUP) ,2001
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993